Rituximab and CC-99282 for older frail patients with large b-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large b-cell lymphoma (a type of blood cancer) and have not had any previous treatment for it.
- You are considered frail based on a special health assessment (age 80 or older and need help with daily activities or have multiple health problems).
- Your doctor has said you cannot receive a common type of chemotherapy called anthracycline-based therapy.
- You have at least one tumor that can be measured by a ct scan (1.5 cm or larger).
- Your blood counts, kidney function, and liver function are within acceptable ranges for the trial.
- You are able to swallow capsules or tablets and can follow the study visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Polatuzumab, Rituximab, and Orelabrutinib) for elderly patients who are frail or over 80 with a specific type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). The goal is to see if this drug combo is safe and effective for those who may not tolerate standard chemotherapy.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
This trial tests a lower-dose combination of chemotherapy drugs (R-mini-MCOP) for people aged 80 or older who have just been diagnosed with a common type of lymphoma called DLBCL. The goal is to see if this gentler approach is effective and easier to tolerate.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This study tests a new immunotherapy drug (epcoritamab) combined with a milder chemotherapy (rituximab-mini CVP) for older or frail patients who cannot receive standard strong chemo. It aims to effectively treat newly diagnosed diffuse large B-cell lymphoma with fewer side effects.
Hear when a new Diffuse Large B Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.